Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
Status:
RECRUITING
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
For patients who met the inclusion criteria, treatment regimens were administered: Rituximab 375 mg/m, intravenously, once weekly for 4 weeks.
Zanubrutinib 160 mg, orally, twice daily for 4 weeks. Combined drugs: prednisone 100 mg/m/d, orally, d1-5; Ruxolitinib 15mg bid orally; With/without emapalumab as appropriate.
Phase:
PHASE4
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University